Patents by Inventor Tianbao Lu

Tianbao Lu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10413545
    Abstract: The present invention is directed to imidazolin-5-one derivatives, pharmaceutical compositions containing them, and their use as FASN inhibitors, in for example, the treatment of cancer, obesity related disorders, and liver related disorders. Such compounds are represented by formula (I) as follows: wherein R1, R2, R3, R4, R5, m, n, and are defined herein.
    Type: Grant
    Filed: June 23, 2017
    Date of Patent: September 17, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Peter J Connolly, Tianbao Lu
  • Publication number: 20190225569
    Abstract: The present invention relates to a method of recycling mother liquid of a PTA refining unit. The present invention recycles waste heat and PT acids of a PTA mother liquid to effectively utilize heat in the PTA mother liquid, solves influence of crystallization of the PT acids on subsequent system, reduces pollution to the environment, and can produce huge economic benefits by using high efficient multistage flash distillation technology, low temperature cogeneration technology, heat pump heating and cooling technology, and low temperature crystallization technology.
    Type: Application
    Filed: May 15, 2017
    Publication date: July 25, 2019
    Inventors: Xu ZHAO, Tao SHEN, Tianbao WANG, Wanyao ZHANG, Yuanrui LU, Lilong XU, Min JIA, Dongzhao HAN, Xiaoling XIE, Yongning QIU
  • Publication number: 20190218186
    Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Application
    Filed: January 8, 2019
    Publication date: July 18, 2019
    Inventors: Guozhang Xu, Micheal Gaul, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
  • Patent number: 10214493
    Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: February 26, 2019
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Micheal Gaul, Guozhang Xu, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
  • Publication number: 20180327401
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including those mediated by inhibition of fatty acid synthase (FASN) enzyme, such as, cancer, obesity or related discorders, and liver related disorders. Such compounds are represented by formula (I) as follows: wherein L1, a, b, m, n, R1, R2, R3, R4, and R5 are defined herein.
    Type: Application
    Filed: July 19, 2018
    Publication date: November 15, 2018
    Inventors: Peter J. Connolly, Gilles C. Bignan, Tianbao Lu, Michael H. Parker, Donald W. Ludovici, Christophe Meyer, Lieven Meerpoel, Karine Smans, Christian Rocaboy
  • Patent number: 10077261
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including those mediated by inhibition of fatty acid synthase (FASN) enzyme, such as, cancer, obesity or related discorders, and liver related disorders. Such compounds are represented by formula (I) as follows: wherein L1, a, b, m, n, R1, R2, R3, R4, and R5 are defined herein.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: September 18, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Peter J. Connolly, Gilles C. Bignan, Tianbao Lu, Michael H. Parker, Donald W. Ludovici, Christophe Meyer, Lieven Meerpoel, Karine Smans, Christian Rocaboy
  • Publication number: 20180170909
    Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.
    Type: Application
    Filed: December 20, 2017
    Publication date: June 21, 2018
    Inventors: Tianbao Lu, Brett Douglas Allison, Joseph Kent Barbay, Peter J. Connolly, Maxwell David Cummings, Gaston Diels, James Patrick Edwards, Kevin D. Kreutter, Ulrike Philippar, Fang Shen, Johannes Wilhelmus John Fitzgerald Thuring, Tongfei Wu
  • Patent number: 10000473
    Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: June 19, 2018
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Micheal Gaul, Guozhang Xu, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
  • Publication number: 20180162899
    Abstract: Disclosed are compounds, compositions and methods for treating viral infections, diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein R1A, R1B, R1c, B1, R2A, and R2B are defined herein.
    Type: Application
    Filed: November 22, 2017
    Publication date: June 14, 2018
    Inventors: Gilles Bignan, Peter Connolly, James Patrick Edwards, Stuart Emanuel, Sylvie Laquerre, Tianbao Lu, Mark Richter, Leonid Beigelman, Santhosh Kumar Thatikonda, Guangyi Wang, Minghong Zhong
  • Publication number: 20180065955
    Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Application
    Filed: September 5, 2017
    Publication date: March 8, 2018
    Inventors: Micheal Gaul, Guozhang Xu, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
  • Publication number: 20180065934
    Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Application
    Filed: September 5, 2017
    Publication date: March 8, 2018
    Inventors: Micheal Gaul, Guozhang Xu, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
  • Publication number: 20170290832
    Abstract: The present invention is directed to imidazolin-5-one derivatives, pharmaceutical compositions containing them, and their use as FASN inhibitors, in for example, the treatment of cancer, obesity related disorders, and liver related disorders.
    Type: Application
    Filed: June 23, 2017
    Publication date: October 12, 2017
    Inventors: Peter J. Connolly, Tianbao Lu
  • Patent number: 9718813
    Abstract: The present invention is directed to imidazolin-5-one derivatives, pharmaceutical compositions containing them, and their use as FASN inhibitors, in for example, the treatment of cancer, obesity related disorders, and liver related disorders. Such compounds are represented by formula (I) as follows: wherein R1, R2, R3, R4, R5, m, n, and are defined herein.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: August 1, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Peter J Connolly, Tianbao Lu
  • Patent number: 9562035
    Abstract: The present invention is directed to benzamide derivatives, pharmaceutical compositions containing them, and their use as FASN inhibitors, in for example, the treatment of cancer, obesity related disorders, liver related disorders and viral infections. Such compounds are represented by formula (I) as follows: wherein R1, R2, R3, R4, R5, m, n, ?are defined herein.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: February 7, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Peter J Connolly, Tianbao Lu
  • Patent number: 9249163
    Abstract: Disclosed are compounds, compositions and methods for treating Type II diabetes and other disorders affected by activity of the enzyme PDE10a. Such compounds are represented by Formula (I) below, wherein R1, R2, L and Q are defined herein.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: February 2, 2016
    Assignee: JANSSEN PHARMACEUTICA NV.
    Inventors: Mark R. Player, Sanath K. Meegalla, Carl R. Illig, Jinsheng Chen, Kenneth J. Wilson, Yu-Kai Lee, Daniel J. Parks, Hui Huang, Sharmila Patel, Tianbao Lu
  • Publication number: 20160009688
    Abstract: The present invention is directed to benzamide derivatives, pharmaceutical compositions containing them, and their use as FASN inhibitors, in for example, the treatment of cancer, obesity related disorders, liver related disorders and viral infections. Such compounds are represented by formula (I) as follows: wherein R1, R2, R3, R4, R5, m, n, are defined herein.
    Type: Application
    Filed: November 21, 2014
    Publication date: January 14, 2016
    Applicant: Janssen Pharmaceutica NV
    Inventors: Peter J Connolly, Tianbao Lu
  • Publication number: 20160002219
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including those mediated by inhibition of fatty acid synthase (FASN) enzyme, such as, cancer, obesity or related discorders, and liver related disorders. Such compounds are represented by formula (I) as follows: wherein L1, a, b, m, n, R1, R2, R3, R4, and R5 are defined herein.
    Type: Application
    Filed: September 11, 2015
    Publication date: January 7, 2016
    Inventors: Peter J. Connolly, Gilles C. Bignan, Tianbao Lu, Michael H. Parker, Donald W. Ludovici, Christophe Meyer, Lieven Meerpoel, Karine Smans, Christian Rocaboy
  • Publication number: 20150166529
    Abstract: The present invention is directed to imidazolin-5-one derivatives, pharmaceutical compositions containing them, and their use as FASN inhibitors, in for example, the treatment of cancer, obesity related disorders, and liver related disorders. Such compounds are represented by formula (I) as follows: wherein R1, R2, R3, R4, R5, m, n, and are defined herein.
    Type: Application
    Filed: December 17, 2014
    Publication date: June 18, 2015
    Inventors: Peter J. Connolly, Tianbao Lu
  • Publication number: 20140364414
    Abstract: Disclosed are compounds, compositions and methods for treating Type II diabetes. Such compounds are represented by Formula (I) as follows: wherein R1, R2, L, and Q are defined herein.
    Type: Application
    Filed: June 9, 2014
    Publication date: December 11, 2014
    Applicant: JANSSEN PHARMACEUTICA, NV
    Inventors: Mark R. Player, Sanath K. Meegalla, Carl R. Illig, Jinsheng Chen, Kenneth J. Wilson, Yu-Kai Lee, Daniel J. Parks, Hui Huang, Sharmila Patel, Tianbao Lu
  • Patent number: 8173654
    Abstract: The invention is directed to triazolopyridazine compounds of Formula I: where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression in a cell or subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to c-Met. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.
    Type: Grant
    Filed: August 7, 2008
    Date of Patent: May 8, 2012
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Tianbao Lu, Richard Alexander, Richard W. Connors, Maxwell D. Cummings, Robert A. Galemmo, Heather Rae Hufnagel, Dana L. Johnson, Ehab Khalil, Kristi A. Leonard, Thomas P. Markotan, Anna C. Maroney, Jan L. Sechler, Jeremy M. Travins, Robert W. Tuman